Cargando…

IDH mutation-specific radiomic signature in lower-grade gliomas

Unravelling the heterogeneity is the central challenge for glioma precession oncology. In this study, we extracted quantitative image features from T2-weighted MR images and revealed that the isocitrate dehydrogenase (IDH) wild type and mutant lower grade gliomas (LGGs) differed in their expression...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Xing, Li, Yiming, Li, Shaowu, Fan, Xing, Sun, Zhiyan, Yang, Zhengyi, Wang, Kai, Zhang, Zhong, Jiang, Tao, Liu, Yong, Wang, Lei, Wang, Yinyan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals 2019
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6366985/ https://www.ncbi.nlm.nih.gov/pubmed/30696801 http://dx.doi.org/10.18632/aging.101769

Ejemplares similares

Radiogenomics of lower-grade gliomas: a radiomic signature as a biological surrogate for survival prediction
por: Qian, Zenghui, et al.
Publicado: (2018)

A radiomic signature as a non-invasive predictor of progression-free survival in patients with lower-grade gliomas
por: Liu, Xing, et al.
Publicado: (2018)

Preoperative Radiomics Analysis of 1p/19q Status in WHO Grade II Gliomas
por: Fan, Ziwen, et al.
Publicado: (2021)

MRI features predict p53 status in lower-grade gliomas via a machine-learning approach
por: Li, Yiming, et al.
Publicado: (2017)

Radiomics Features Predict Telomerase Reverse Transcriptase Promoter Mutations in World Health Organization Grade II Gliomas via a Machine-Learning Approach
por: Fang, Shengyu, et al.
Publicado: (2021)

IDH mutations but not TERTp mutations are associated with seizures in lower-grade gliomas
por: Duan, Wen-chao, et al.
Publicado: (2018)

Radiogenomic analysis of vascular endothelial growth factor in patients with diffuse gliomas
por: Sun, Zhiyan, et al.
Publicado: (2019)

Molecular profiles of tumor contrast enhancement: A radiogenomic analysis in anaplastic gliomas
por: Liu, Xing, et al.
Publicado: (2018)

Seizures in patients with IDH-mutated lower grade gliomas
por: Carstam, Louise, et al.
Publicado: (2022)

Predicting the Type of Tumor-Related Epilepsy in Patients With Low-Grade Gliomas: A Radiomics Study
por: Wang, Yinyan, et al.
Publicado: (2020)

Radiomics Analysis of Postoperative Epilepsy Seizures in Low-Grade Gliomas Using Preoperative MR Images
por: Sun, Kai, et al.
Publicado: (2020)

IDH mutation status is associated with distinct vascular gene expression signatures in lower-grade gliomas
por: Zhang, Lei, et al.
Publicado: (2018)

Radiomics analysis allows for precise prediction of epilepsy in patients with low-grade gliomas
por: Liu, Zhenyu, et al.
Publicado: (2018)

Association of tumor growth rates with molecular biomarker status: a longitudinal study of high-grade glioma
por: Fan, Ziwen, et al.
Publicado: (2020)

ADAM9 Expression Is Associate with Glioma Tumor Grade and Histological Type, and Acts as a Prognostic Factor in Lower-Grade Gliomas
por: Fan, Xing, et al.
Publicado: (2016)

Predicting IDH Mutation Status in Low-Grade Gliomas Based on Optimal Radiomic Features Combined with Multi-Sequence Magnetic Resonance Imaging
por: He, Ailing, et al.
Publicado: (2022)

The Value of Enhanced MR Radiomics in Estimating the IDH1 Genotype in High-Grade Gliomas
por: Niu, Lei, et al.
Publicado: (2020)

Identifying biomarkers associated with tumor growth rate: a longitudinal preoperative magnetic resonance imaging follow-up of low-grade gliomas
por: Liu, Yukun, et al.
Publicado: (2022)

Hypermethylation of LATS2 Promoter and Its Prognostic Value in IDH-Mutated Low-Grade Gliomas
por: Gu, Yuan, et al.
Publicado: (2020)

An Immune-Related Prognostic Signature for Predicting Clinical Outcomes and Immune Landscape in IDH-Mutant Lower-Grade Gliomas
por: Xiao, Gang, et al.
Publicado: (2021)

Radiomics Features Predict CIC Mutation Status in Lower Grade Glioma
por: Zhang, Luyuan, et al.
Publicado: (2020)

MEGF10, a Glioma Survival-Associated Molecular Signature, Predicts IDH Mutation Status
por: Li, Guanzhang, et al.
Publicado: (2018)

Development and Validation of an IDH1-Associated Immune Prognostic Signature for Diffuse Lower-Grade Glioma
por: Deng, Xiangyang, et al.
Publicado: (2019)

The comparison of clinical and biological characteristics between IDH1 and IDH2 mutations in gliomas
por: Wang, Hao-Yuan, et al.
Publicado: (2016)

Multicenter DSC–MRI-Based Radiomics Predict IDH Mutation in Gliomas
por: Manikis, Georgios C., et al.
Publicado: (2021)

Pharmacoresistant seizures and IDH mutation in low-grade gliomas
por: Correia, Carlos Eduardo, et al.
Publicado: (2021)

Deep Learning based Radiomics (DLR) and its usage in noninvasive IDH1 prediction for low grade glioma
por: Li, Zeju, et al.
Publicado: (2017)

A Novel TNFSF-Based Signature Predicts the Prognosis and Immunosuppressive Status of Lower-Grade Glioma
por: Tao, Rui, et al.
Publicado: (2022)

Radiomics-Based Method for Predicting the Glioma Subtype as Defined by Tumor Grade, IDH Mutation, and 1p/19q Codeletion
por: Li, Yingping, et al.
Publicado: (2022)

Vessel Size Imaging is Associated with IDH Mutation and Patient Survival in Diffuse Lower-Grade Glioma
por: Kang, Houyi, et al.
Publicado: (2020)

Precision Oncology in Lower-Grade Gliomas: Promises and Pitfalls of Therapeutic Strategies Targeting IDH-Mutations
por: Persico, Pasquale, et al.
Publicado: (2022)

Isocitrate dehydrogenase 1 (IDH1) mutation-specific microRNA signature predicts favorable prognosis in glioblastoma patients with IDH1 wild type
por: Wang, Zheng, et al.
Publicado: (2013)

MPC-01 PROGNOSTIC ROLE OF TERT PROMOTER IMPROVES THE STRATIFICATION OF IDH-MUTATED LOWER GRADE GLIOMA
por: Arita, Hideyuki, et al.
Publicado: (2019)

Predicting prognosis and IDH mutation status for patients with lower-grade gliomas using whole slide images
por: Jiang, Shuai, et al.
Publicado: (2021)

Lesion location implemented magnetic resonance imaging radiomics for predicting IDH and TERT promoter mutations in grade II/III gliomas
por: Arita, Hideyuki, et al.
Publicado: (2018)

RFC2: a prognosis biomarker correlated with the immune signature in diffuse lower-grade gliomas
por: Zhao, Xu, et al.
Publicado: (2022)

DZIP3 is a key factor to stratify IDH1 wild-type lower-grade gliomas
por: Liang, Tingyu, et al.
Publicado: (2020)

Construction of a prognostic immune signature for lower grade glioma that can be recognized by MRI radiomics features to predict survival in LGG patients
por: Li, Zi-zhuo, et al.
Publicado: (2021)

Prediction of TERTp-mutation status in IDH-wildtype high-grade gliomas using pre-treatment dynamic [(18)F]FET PET radiomics
por: Li, Zhicong, et al.
Publicado: (2021)

IDH1 mutation impairs antiviral response and potentiates oncolytic virotherapy in glioma
por: Chen, Xueqin, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_kldvnivoac6i3rcckt637btabs